Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan.
Showa University Clinical Research Institute for Clinical Pharmacology and Therapeutics, 1-5-8 Hatanodai, Shinagawa, Tokyo, 142-8555, Japan.
Surg Today. 2020 Dec;50(12):1560-1577. doi: 10.1007/s00595-020-01968-x. Epub 2020 Feb 5.
Digestive system cancers are the most frequent cancers worldwide and often associated with poor prognosis because of their invasive and metastatic characteristics. Recent studies have found that the plasticity of cancer cells can impart cancer stem-like properties via the epithelial-mesenchymal transition (EMT). Cancer stem-like properties such as tumor initiation are integral to the formation of metastasis, which is the main cause of poor prognosis. Numerous markers of cancer stem cells (CSCs) have been identified in many types of cancer. Therefore, CSCs, via their stem cell-like functions, may play an important role in prognosis after surgery. While several reports have described prognostic analysis using CSC markers, few reviews have summarized CSCs and their association with prognosis. Herein, we review the prognostic potential of eight CSC markers, CD133, CD44, CD90, ALDH1A1, EPCAM, SOX2, SOX9, and LGR5, in digestive cancers including those of the pancreas, colon, liver, gastric, and esophagus.
消化系统癌症是全球最常见的癌症，由于其侵袭性和转移性特征，往往预后不良。最近的研究发现，癌细胞的可塑性可以通过上皮-间充质转化（EMT）赋予癌症干细胞样特性。癌症干细胞样特性，如肿瘤起始，是转移形成的关键，这是预后不良的主要原因。在许多类型的癌症中已经鉴定出许多癌症干细胞（CSC）的标志物。因此，CSC 可能通过其干细胞样功能在手术后的预后中发挥重要作用。虽然有几项报告描述了使用 CSC 标志物进行预后分析，但很少有综述总结了 CSC 及其与预后的关系。在此，我们综述了包括胰腺、结肠、肝、胃和食管在内的消化系统癌症中 8 种 CSC 标志物（CD133、CD44、CD90、ALDH1A1、EPCAM、SOX2、SOX9 和 LGR5）的预后潜力。
